Patients with rheumatoid arthritis (RA) with inadequate response to methotrexate report clinically meaningful improvements across a broad range of outcomes after adding either tofacitinib (Xeljanz) or adalimumab (Humira), a new analysis shows. After 3 …
(Visited 4 times, 1 visits today)
){kind=link}
Comments
Comments are disabled for this post.